Multiple Tumor Types

Viewing Page 5 of 7 | Showing Results 41 - 50 of 61

A Phase I, first-in-human, dose-escalation study to evaluate the safety and immunologic response after administration of HS-130 in combination with HS-110 (viagenpumatucel-L) in patients with solid tumors refractory to standard care

This is a phase 1 open-label, single center, dose escalation study to determine a safe and effective maximum tolerated dose of HS-130 in...

Rachel Sanborn, M.D.
  • Oncology and Hematology Care Westside
  • Providence Cancer Institute Franz Clinic

John Wayne Cancer Institute Biospecimen Repository Protocol

When cancer patients undergo procedures such as biopsies or surgery in which malignant tissue is removed for diagnostic or therapeutic purposes, it...

Jennifer Linehan, M.D.
  • John Wayne Cancer Institute (JWCI)
  • Providence St. Johns Health Center (PSJHC)

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability,...

Rom Leidner, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AO-176

This is a first-in-human, Phase 1 multi-center, open-label, dose escalation and expansion study of AO-176 which will evaluate the safety,...

Jacob Thomas, M.D.
  • Hoag Research
  • xSJH Southern California

ABSCOPAL An observational study to assess the anti-tumor response in non-irradiated lesions (Abscopal effect) in patients with metastatic solid tumors who receive radiation while on immunotherapy.

To evaluate the rate of response in non-irradiated lesions in patients receiving radiation while on immunotherapy. This is measurable by RECIST...

Peter Jiang, M.D., Ph.D.
  • Everett Clinic

A Phase 1 Study of SGN-TGT in Subjects with Advanced Malignancies

This trial will look at a drug called SGN-TGT to find out whether it is safe for patients with solid tumors and lymphomas. It will study SGN-TGT to...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

CriteriaPartial Inclusion Criteria:Patient with advanced or metastatic solid tumor and has disease progression or treatment intolerance after...

Ying Zhuo, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research

AN OPEN-LABEL, PHASE 2 STUDY OF NERATINIB IN PATIENTS WITH SOLID TUMORS WITH SOMATIC HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR, HER2, HER3) MUTATIONS OR EGFR GENE AMPLIFICATION

The purpose of this study is to find our what effects, good and/or bad, neratinib either by itself (monotherapy) or in combination with other drugs...

Diana Hanna, M.D.
  • Hoag Research
  • xSJH Southern California

A Phase 1/2 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)

A Phase 1 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors Harboring RET Alterations

Michael Demeure, M.D.
  • Hoag Research
  • xSJH Southern California

A phase 1 study of SGN-CD47M in patients with advanced solid tumors.

This trial will study SGN-CD47M to find out whether it is an effective treatment for different types of solid tumors and what side effects...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic
Viewing Page 5 of 7 | Showing Results 41 - 50 of 61